4 results on '"Fang LIU"'
Search Results
2. No MERS-CoV but positive influenza viruses in returning Hajj pilgrims, China, 2013-2015.
- Author
-
Xuezheng Ma, Fang Liu, Lijuan Liu, Liping Zhang, Mingzhu Lu, Abudukadeer, Abuduzhayier, Lingbing Wang, Feng Tian, Wei Zhen, Pengfei Yang, Kongxin Hu, Ma, Xuezheng, Liu, Fang, Liu, Lijuan, Zhang, Liping, Lu, Mingzhu, Wang, Lingbing, Tian, Feng, Zhen, Wei, and Yang, Pengfei
- Subjects
- *
MERS coronavirus , *MUSLIM pilgrims & pilgrimages , *MUSLIMS , *INFLUENZA viruses , *HUMAN metapneumovirus infection , *DISEASES , *INFLUENZA diagnosis , *RNA metabolism , *INFLUENZA epidemiology , *CORONAVIRUS diseases , *INFLUENZA , *ORTHOMYXOVIRUSES , *POLYMERASE chain reaction , *RESEARCH funding , *RESPIRATORY syncytial virus , *RNA , *DIAGNOSIS - Abstract
Background: There is global health concern that the mass movement of pilgrims to and from Mecca annually could contribute to the international spread of Middle East Respiratory Syndrome Coronavirus (MERS-CoV). In China, about 11,000 Muslim pilgrims participate in the Hajj gathering in Mecca annually. This is the first report of MERS-CoV and respiratory virus molecular screening of returning pilgrims at points of entry in China from 2013 to 2015.Methods and Results: A total of 847 returning Hajj pilgrims participated in this study. The test results indicated that of the travelers, 34 tested positive for influenza A virus, 14 for influenza B virus, 4 for metapneumo virus, 2 for respiratory syncytial virus, and 3 for human coronavirus. There was a significant difference in the rates of positive and negative influenza virus tests between Hajj pilgrims with symptoms and those without. The detection rates of influenza virus were not significantly different among the three years studied, at 5.3, 6.0 and 6.3% for 2013, 2014 and 2015, respectively. DISCUSSION AND CONCLUSION: The MERS-CoV and respiratory viruses detection results at points of entry in China from 2013 to 2015 indicated that there were no MERS-CoV infection but a 5.7% positive influenza viruses in returning Chinese pilgrims. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
3. The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials.
- Author
-
Fang Liu, Hong-Mei Wang, Tiansheng Wang, Ya-Mei Zhang, Xi Zhu, Liu, Fang, Wang, Hong-Mei, Wang, Tiansheng, Zhang, Ya-Mei, and Zhu, Xi
- Subjects
- *
THYMOSIN , *INFLAMMATION treatment , *SEPSIS , *META-analysis , *RANDOMIZED controlled trials , *MORTALITY , *TREATMENT effectiveness , *PATIENTS , *IMMUNOLOGICAL adjuvants , *TUMOR necrosis factors , *APACHE (Disease classification system) , *ARTIFICIAL respiration , *CLINICAL trials , *COMPARATIVE studies , *CYTOKINES , *LENGTH of stay in hospitals , *INTENSIVE care units , *INTERLEUKINS , *RESEARCH methodology , *MEDICAL cooperation , *MULTIPLE organ failure , *PEPTIDE hormones , *RESEARCH , *T cells , *SYSTEMATIC reviews , *EVALUATION research , *LYMPHOCYTE subsets , *PREVENTION , *THERAPEUTICS - Abstract
Background: Thymosin α1 (Tα1) as immunomodulatory treatment is supposed to be beneficial for the sepsis patients by regulating T cell subsets and inflammatory mediators. However, limited by the small sample size and the poor study design, the persuasive power of the single clinical studies is weak. This meta-analysis aimed to investigate the impact of Tα1 on the sepsis patients.Methods: We searched for the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CBM, VIP, CNKI, WANFANG, Igaku Chuo Zasshi (ICHUSHI) and Korean literature databases reporting the effects of Tα1 on outcomes in sepsis patients.Results: Among 444 related articles, 19 randomized controlled trials (RCTs) met our inclusion criteria. Mortality events were reported in 10 RCTs included 530 patients, and the meta-analysis showed significant decrease in Tα1 group compared with control group (RR 0.59, 95 % CI 0.45 to 0.77, p = 0.0001). The subgroup analysis showed no difference between the two dosages (RR 0.59, 95 % CI 0.43 to 0.81; RR 0.59, 95 % CI 0.35 to 0.98, respectively). In 9 RCTs, with a total of 489 patients, Tα1 administered once per day decrease APACHE II score significantly (SMD -0.80, 95 % CI -1.14 to -0.47, p < 0.0001) while Tα1 twice per day showed no effect (SMD 0.30, 95 % CI-0.10 to 0.70, p = 0.14). However, the length of ICU stay, the incidence of multiple organ failure (MOF) and duration of mechanical ventilation were not significantly affected by Tα1 treatment (SMD -0.52, 95 % CI -1.06 to 0.11, p = 0.06; SMD -0.49, 95 % CI -1.09 to 0.11, p = 0.11; SMD -0.37, 95 % CI -0.90 to 0.17, p = 0.17, respectively). As to the immunological indicators, the level of HLA-DR were increased by Tα1 (SMD 1.23, 95 % CI 0.28 to 2.18, p = 0.01) according to the pooled analysis of 8 studies involving 721 patients. Lymphocyte subsets CD3, CD4 and cytokines IL-6, IL-10 and TNF-α were also beneficially affected by Tα1 treatment.Conclusions: Tα1 may be beneficial to sepsis patients in reducing mortality and modulating inflammation reactions. However, the quality of evidence supporting the effectiveness is low considering the small sample sizes and inadequate adherence to standardized reporting guidelines for RCTs among the included studies. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
4. Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients.
- Author
-
Wang Liang, Xiao-fang Liu, Jun Huang, De-mei Zhu, Jian Li, and Jing Zhang
- Subjects
- *
DRUG resistance , *ACINETOBACTER infections , *POLYMERASE chain reaction , *INTENSIVE care units , *RIFAMPIN - Abstract
Background: Extensive drug resistance of Acinetobacter baumannii is a serious problem in the clinical setting. It is therefore important to find active antibiotic combinations that could be effective in the treatment of infections caused by this problematic 'superbug'. In this study, we analyzed the in vitro activities of three colistin-based combinations and a minocycline-based combination against clinically isolated extensive drug resistant Acinetobacter baumannii (XDR-AB) strains. Methods: Fourteen XDR-AB clinical isolates were collected. The clonotypes were determined by polymerase chain reaction-based fingerprinting. Susceptibility testing was carried out according to the standards of the Clinical and Laboratory Standards Institute. Activities of drug combinations were investigated against four selected strains and analyzed by mean survival time over 12 hours (MST12 h) in a time-kill study. Results: The time-kill studies indicated that the minimum inhibitory concentration (MIC) of colistin (0.5 or 0.25 μg/ mL) completely killed all strains at 2 to 4 hours, but 0.5xMIC colistin showed no bactericidal activity. Meropenem (8 μg/mL), minocycline (1 μg/mL) or rifampicin (0.06 μg/mL) did not show bactericidal activity. However, combinations of colistin at 0.5xMIC (0.25 or 0.125 μg/mL) with each of the above were synergistic and shown bactericidal activities against all test isolates. A combination of meropenem (16 μg/mL) with minocycline (0.5xMIC, 4 or 2 μg/mL) was synergitic to all test isolates, but neither showed bactericidal activity alone. The MST12 h values of drug combinations (either colistin- or minocycline-based combinations) were significantly shorter than those of the single drugs (p < 0.01). Conclusions: This study indicates that combinations of colistin/meropenem, colistin/rifampicin, colistin/minocycline and minocycline/meropenem are synergistic in vitro against XDR-AB strains. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.